Data Integrity And The Iceberg Concern
US FDA official outlines a number of issues around data integrity lapses, including how they trigger concern around all records of a non-compliant firm and that certain factors, including the limited oversight of sponsors over CMOs, could potentially be linked with data integrity problems.
You may also be interested in...
Against a backdrop of US FDA warnings and global regulatory convergence, the Indian pharma industry is looking to build in quality from project inception and foster an unbiased approach to quality across global markets, a conference in Mumbai hears.
Now that US FDA has approved the final EU authority, mutual recognition efforts could expand and deepen. Former FDA chief counsel Rebecca Wood discusses the future of approval standards harmonization in Pink Sheet interview.
Former US FDA Deputy Commissioner for Global Regulatory Operations and Policy, Howard Sklamberg, shares his views at a conference in India on a range of issues, including the need for formal policy mechanisms to help infuse improved objectivity around Form 483 observations and challenges on evaluating quality culture.